US7119184B2
(en)
*
|
1991-08-12 |
2006-10-10 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
JP4148662B2
(ja)
*
|
2000-08-10 |
2008-09-10 |
第一三共株式会社 |
ヌクレオシド及びオリゴヌクレオチド類縁体を含有する核酸試薬及び医薬
|
JP4151751B2
(ja)
*
|
1999-07-22 |
2008-09-17 |
第一三共株式会社 |
新規ビシクロヌクレオシド類縁体
|
ATE325806T1
(de)
|
2000-10-04 |
2006-06-15 |
Santaris Pharma As |
Verbesserte synthese von purin-blockierten nukleinsäure-analoga
|
GB0114719D0
(en)
*
|
2001-06-15 |
2001-08-08 |
Glaxo Group Ltd |
Compound
|
WO2003033696A1
(fr)
*
|
2001-10-18 |
2003-04-24 |
Sankyo Company, Limited |
Compose antisens vegf
|
EP1481983A4
(de)
|
2002-02-13 |
2008-04-02 |
Takeshi Imanishi |
Nukleosidanaloga und oligonukleotidderivat, das ein nukleotidanalogon davon enthält
|
US20040219565A1
(en)
|
2002-10-21 |
2004-11-04 |
Sakari Kauppinen |
Oligonucleotides useful for detecting and analyzing nucleic acids of interest
|
WO2004044139A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Parmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
US7696345B2
(en)
|
2002-11-05 |
2010-04-13 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US7687617B2
(en)
|
2002-11-18 |
2010-03-30 |
Santaris Pharma A/S |
Oligonucleotides with alternating segments of locked and non-locked nucleotides
|
AU2013201763B2
(en)
*
|
2002-11-18 |
2015-05-07 |
Roche Innovation Center Copenhagen A/S |
Amino-LNA, thio-LNA and alpha-L-oxy-LN
|
TWI347948B
(en)
*
|
2002-11-19 |
2011-09-01 |
Sankyo Co |
Novel 2',5'-oligoadenylic acid compositions
|
JP5132025B2
(ja)
*
|
2002-11-19 |
2013-01-30 |
第一三共株式会社 |
新規2’,5’−オリゴアデニル酸類縁体
|
CA3001404C
(en)
*
|
2002-11-25 |
2020-07-28 |
Masafumi Matsuo |
Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors
|
ES2385828T3
(es)
|
2003-06-20 |
2012-08-01 |
Exiqon A/S |
Sondas, bibliotecas y kits para análisis de mezclas de ácidos nucleicos y procedimientos para construirlos
|
US7683036B2
(en)
|
2003-07-31 |
2010-03-23 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
|
JP4731324B2
(ja)
*
|
2003-08-28 |
2011-07-20 |
武 今西 |
N−o結合性架橋構造型新規人工核酸
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
US7480382B2
(en)
*
|
2003-09-30 |
2009-01-20 |
Microsoft Corporation |
Image file container
|
GB0324854D0
(en)
*
|
2003-10-24 |
2003-11-26 |
Expresson Biosystems Ltd |
App/ena antisense
|
DE602004015832D1
(de)
*
|
2003-11-07 |
2008-09-25 |
Daiichi Sankyo Co Ltd |
Verfahren zum nachweis von genetischem polymorphismus
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
TW200540180A
(en)
*
|
2004-05-28 |
2005-12-16 |
Sankyo Co |
Telomerase inhibitor ena oligonucleotide
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
WO2006059507A1
(ja)
*
|
2004-11-30 |
2006-06-08 |
Sankyo Company, Limited |
11β-HSD1アンチセンス化合物
|
EP1871913A2
(de)
*
|
2005-03-25 |
2008-01-02 |
Ambion, Inc. |
Verfahren und zusammensetzungen zur verringerung abundanter rna-transkripte
|
EP2338992A3
(de)
|
2005-08-29 |
2011-10-12 |
Regulus Therapeutics, Inc |
Antisense-verbindungen mit verbesserter anti-mikrorna-aktivität
|
US9862770B2
(en)
|
2005-10-19 |
2018-01-09 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
US20100226884A1
(en)
|
2009-01-20 |
2010-09-09 |
Immunomedics, Inc. |
Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
|
US8883162B2
(en)
*
|
2005-10-19 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
CA2631931C
(en)
|
2005-12-01 |
2014-04-29 |
Pronai Therapeutics, Inc. |
Cancer therapies and pharmaceutical compositions used therein
|
KR101404374B1
(ko)
*
|
2005-12-09 |
2014-06-09 |
도꾸리쯔교세이호징 리가가쿠 겐큐소 |
핵산의 복제방법 및 신규한 인공 염기쌍
|
US8288354B2
(en)
|
2005-12-28 |
2012-10-16 |
The Scripps Research Institute |
Natural antisense and non-coding RNA transcripts as drug targets
|
WO2007090073A2
(en)
|
2006-01-27 |
2007-08-09 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for the use in modulation of micrornas
|
JP5342881B2
(ja)
|
2006-01-27 |
2013-11-13 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
6−修飾された二環式核酸類似体
|
DK2015758T3
(da)
|
2006-05-05 |
2014-06-23 |
Isis Pharmaceuticals Inc |
Forbindelser og fremgangsmåder til modulering af ekspression af apob
|
EP2505649A1
(de)
|
2006-05-05 |
2012-10-03 |
Isis Pharmaceuticals, Inc. |
Verbindungen und Verfahren zur Modulation der Expression von GCGR
|
US7547684B2
(en)
|
2006-05-11 |
2009-06-16 |
Isis Pharmaceuticals, Inc. |
5′-modified bicyclic nucleic acid analogs
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
ES2377327T5
(es)
|
2006-10-18 |
2020-04-28 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido
|
TW200838551A
(en)
*
|
2006-11-27 |
2008-10-01 |
Isis Pharmaceuticals Inc |
Methods for treating hypercholesterolemia
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
US20100292301A1
(en)
*
|
2007-02-28 |
2010-11-18 |
Elena Feinstein |
Novel sirna structures
|
US8278425B2
(en)
|
2007-05-30 |
2012-10-02 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
WO2008154401A2
(en)
|
2007-06-08 |
2008-12-18 |
Isis Pharmaceuticals, Inc. |
Carbocyclic bicyclic nucleic acid analogs
|
US20110046206A1
(en)
*
|
2007-06-22 |
2011-02-24 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
AU2008272918B2
(en)
|
2007-07-05 |
2012-09-13 |
Isis Pharmaceuticals, Inc. |
6-disubstituted bicyclic nucleic acid analogs
|
CA2700953A1
(en)
|
2007-10-02 |
2009-04-09 |
Amgen Inc. |
Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
|
AU2008306455C1
(en)
*
|
2007-10-03 |
2014-04-17 |
Quark Pharmaceuticals, Inc. |
Novel siRNA structures
|
US8546556B2
(en)
*
|
2007-11-21 |
2013-10-01 |
Isis Pharmaceuticals, Inc |
Carbocyclic alpha-L-bicyclic nucleic acid analogs
|
US20110105584A1
(en)
*
|
2007-12-12 |
2011-05-05 |
Elena Feinstein |
Rtp80il sirna compounds and methods of use thereof
|
US8614311B2
(en)
|
2007-12-12 |
2013-12-24 |
Quark Pharmaceuticals, Inc. |
RTP801L siRNA compounds and methods of use thereof
|
WO2009090639A2
(en)
*
|
2008-01-15 |
2009-07-23 |
Quark Pharmaceuticals, Inc. |
Sirna compounds and methods of use thereof
|
EP2265627A2
(de)
|
2008-02-07 |
2010-12-29 |
Isis Pharmaceuticals, Inc. |
Bicyclische cyclohexitolnukleinsäureanaloga
|
JP5697993B2
(ja)
|
2008-02-11 |
2015-04-08 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
修飾RNAiポリヌクレオチドおよびその使用
|
RU2010138558A
(ru)
*
|
2008-03-20 |
2012-03-27 |
Кварк Фармасьютикалс. Инк, (Us) |
Новые соединения миphk для ингибирования rtp801
|
DK2285819T3
(da)
|
2008-04-04 |
2013-12-02 |
Isis Pharmaceuticals Inc |
Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider
|
WO2009144704A2
(en)
*
|
2008-04-15 |
2009-12-03 |
Quark Pharmaceuticals, Inc. |
siRNA COMPOUNDS FOR INHIBITING NRF2
|
AU2009256243A1
(en)
|
2008-06-04 |
2009-12-10 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression through endogenous small RNA targeting of gene promoters
|
EP2293800B1
(de)
|
2008-06-06 |
2016-10-05 |
Quark Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von ohrerkrankungen
|
TWI455944B
(zh)
|
2008-07-01 |
2014-10-11 |
Daiichi Sankyo Co Ltd |
雙股多核苷酸
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
AU2009276763B2
(en)
|
2008-07-29 |
2015-07-16 |
The Board Of Regents Of The University Of Texas Sytem |
Selective inhibition of polyglutamine protein expression
|
NZ601660A
(en)
*
|
2008-08-25 |
2014-05-30 |
Excaliard Pharmaceuticals Inc |
Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
|
EP2340309A2
(de)
|
2008-09-22 |
2011-07-06 |
Rxi Pharmaceuticals Corporation |
Neutrale nanotransporter
|
DK2356129T3
(da)
|
2008-09-24 |
2013-05-13 |
Isis Pharmaceuticals Inc |
Substituerede alpha-L-bicykliske nukleosider
|
EP2352830B1
(de)
*
|
2008-10-03 |
2019-01-16 |
CuRNA, Inc. |
Behandlung von krankheiten in verbindung mit apolipoprotein a1 durch hemmung eines natürlichen antisense-transkripts gegen apolipoprotein a1
|
US9074211B2
(en)
|
2008-11-19 |
2015-07-07 |
Rxi Pharmaceuticals Corporation |
Inhibition of MAP4K4 through RNAI
|
WO2010065671A2
(en)
*
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
|
CA2745329C
(en)
|
2008-12-04 |
2022-07-12 |
Opko Curna, Llc |
Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
|
KR20110091796A
(ko)
|
2008-12-04 |
2011-08-12 |
오피케이오 큐알엔에이, 엘엘씨 |
종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
|
CA2746508A1
(en)
|
2008-12-17 |
2010-07-15 |
Avi Biopharma, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
US20110288155A1
(en)
|
2008-12-18 |
2011-11-24 |
Elena Feinstein |
Sirna compounds and methods of use thereof
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
US9745574B2
(en)
|
2009-02-04 |
2017-08-29 |
Rxi Pharmaceuticals Corporation |
RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
EP2396038B1
(de)
|
2009-02-12 |
2015-10-21 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem brain-derived neurotrophen faktor (bdnf) mittels hemmung des natürlichen antisense-transkripts gegen bdnf
|
ES2656290T3
(es)
|
2009-03-16 |
2018-02-26 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor nuclear (derivado de eritroide 2) similar al 2 (NRF2) mediante inhibición del transcrito antisentido natural a NRF2
|
CA2755404C
(en)
|
2009-03-17 |
2020-03-24 |
Joseph Collard |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
US8815586B2
(en)
|
2009-04-24 |
2014-08-26 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression using oligomers that target gene regions downstream of 3′ untranslated regions
|
DE102009019476A1
(de)
*
|
2009-05-04 |
2010-11-11 |
Biametrics Marken Und Rechte Gmbh |
Wiedererkennbarer Träger für optische Meßverfahren
|
ES2609655T3
(es)
|
2009-05-06 |
2017-04-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
|
CN106237345A
(zh)
|
2009-05-06 |
2016-12-21 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
CA3185821A1
(en)
|
2009-05-08 |
2010-11-11 |
Curna, Inc. |
Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
|
EP2432881B1
(de)
|
2009-05-18 |
2017-11-15 |
CuRNA, Inc. |
Behandlung von krankheiten im zusammenhang mit dem reprogrammierungsfaktor durch hemmung des natürlichen antisense-transkripts zu einem reprogrammierungsfaktor
|
KR101703695B1
(ko)
|
2009-05-22 |
2017-02-08 |
큐알엔에이, 인크. |
전사 인자 e3(tfe3)에 대한 천연 안티센스 전사체의 억제에 의해 tfe3 및 인슐린 수용체 기질 2(irs2)의 치료
|
US8791085B2
(en)
|
2009-05-28 |
2014-07-29 |
Curna, Inc. |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
DK3276004T3
(da)
|
2009-06-08 |
2020-04-06 |
Quark Pharmaceuticals Inc |
Fremgangsmåder til behandling af kronisk nyresygdom
|
KR101801404B1
(ko)
|
2009-06-16 |
2017-12-20 |
큐알엔에이, 인크. |
콜라겐 유전자에 대한 천연 안티센스 전사체의 억제에 의한 콜라겐 유전자 관련된 질환의 치료
|
EP2443238B1
(de)
|
2009-06-16 |
2017-03-22 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit paraoxonase 1 (pon1) mittels hemmung des natürlichen antisense-transkripts gegen pon 1
|
JP6073133B2
(ja)
|
2009-06-24 |
2017-02-01 |
クルナ・インコーポレーテッド |
腫瘍壊死因子受容体2(tnfr2)に対する天然アンチセンス転写物の抑制によるtnfr2関連疾患の治療
|
US8921330B2
(en)
|
2009-06-26 |
2014-12-30 |
Curna, Inc. |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
WO2011011700A2
(en)
|
2009-07-24 |
2011-01-27 |
Curna, Inc. |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
WO2011017516A2
(en)
|
2009-08-05 |
2011-02-10 |
Curna, Inc. |
Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
|
WO2011017521A2
(en)
|
2009-08-06 |
2011-02-10 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
ES2599986T3
(es)
|
2009-08-11 |
2017-02-06 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con adiponectina (ADIPOQ) mediante la inhibición de un transcrito antisentido natural de una adiponectina (ADIPOQ)
|
CN102482670B
(zh)
|
2009-08-21 |
2018-06-15 |
库尔纳公司 |
通过抑制‘hsp70-相互作用蛋白的c末端’(chip)的天然反义转录物而治疗chip相关疾病
|
KR101892760B1
(ko)
|
2009-08-25 |
2018-08-28 |
큐알엔에이, 인크. |
IQGAP에 대한 천연 안티센스 전사체의 억제에 의한 GTPase 활성화 단백질을 함유하는 IQ 모티프(IQGAP)와 관련된 질환의 치료
|
NO2480669T3
(de)
|
2009-09-25 |
2018-04-07 |
|
|
TW201120055A
(en)
|
2009-10-30 |
2011-06-16 |
Daiichi Sankyo Co Ltd |
Modified double strand polynucleotides
|
WO2011053994A1
(en)
|
2009-11-02 |
2011-05-05 |
Alnylam Pharmaceuticals, Inc. |
Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
|
EP3434773A3
(de)
|
2009-12-09 |
2019-04-17 |
Nitto Denko Corporation |
Modulation der hsp47-expression
|
WO2011072091A1
(en)
|
2009-12-09 |
2011-06-16 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the cns
|
KR101823702B1
(ko)
|
2009-12-16 |
2018-01-30 |
큐알엔에이, 인크. |
막 결합 전사 인자 펩티다제, 부위 1(mbtps1)에 대한 천연 안티센스 전사체의 억제에 의한 mbtps1 관련 질환의 치료
|
ES2661387T3
(es)
|
2009-12-23 |
2018-03-28 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor de crecimiento de hepatocitos (hgf) mediante inhibición del transcrito antisentido natural a hgf
|
CN102781480B
(zh)
|
2009-12-23 |
2018-07-27 |
库尔纳公司 |
通过抑制解偶联蛋白2(ucp2)的天然反义转录物而治疗ucp2相关疾病
|
CN102770540B
(zh)
|
2009-12-29 |
2017-06-23 |
库尔纳公司 |
通过抑制肿瘤蛋白63(p63)的天然反义转录物而治疗p63相关疾病
|
CA2785173A1
(en)
|
2009-12-29 |
2011-07-28 |
Curna, Inc. |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
ES2677044T3
(es)
|
2009-12-31 |
2018-07-27 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el sustrato 2 del receptor de insulina (IRS2) mediante inhibición de transcrito antisentido natural para el IRS2 y factor de transcripción E3 (TFE3)
|
CA2785832A1
(en)
|
2010-01-04 |
2011-07-07 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
|
KR101853509B1
(ko)
|
2010-01-06 |
2018-04-30 |
큐알엔에이, 인크. |
췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
NO2524039T3
(de)
|
2010-01-11 |
2018-04-28 |
|
|
US8779118B2
(en)
|
2010-01-11 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
JP5981850B2
(ja)
|
2010-01-25 |
2016-08-31 |
カッパーアールエヌエー,インコーポレイテッド |
RNaseH1に対する天然アンチセンス転写物の阻害によるRNaseH1関連疾患の治療
|
US9574191B2
(en)
|
2010-02-03 |
2017-02-21 |
The Board Of Regents Of The University Of Texas System |
Selective inhibition of polyglutamine protein expression
|
JP5976548B2
(ja)
|
2010-02-22 |
2016-08-23 |
カッパーアールエヌエー,インコーポレイテッド |
Pycr1に対する天然アンチセンス転写物の阻害によるピロリン−5−カルボン酸レダクターゼ1(pycr1)関連疾患の治療
|
BR112012022946A2
(pt)
|
2010-03-12 |
2017-02-07 |
Daiichi Sankyo Co Ltd |
método para proliferar cardiomiócitos usando micro-rna
|
US9193752B2
(en)
|
2010-03-17 |
2015-11-24 |
Isis Pharmaceuticals, Inc. |
5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
CN106074591B
(zh)
|
2010-03-24 |
2020-01-14 |
菲奥医药公司 |
眼部症候中的rna干扰
|
CN103108642B
(zh)
|
2010-03-24 |
2015-09-23 |
雷克西制药公司 |
皮肤与纤维化症候中的rna干扰
|
WO2011119852A1
(en)
|
2010-03-24 |
2011-09-29 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering rnai compounds
|
CN102869777B
(zh)
|
2010-04-02 |
2018-11-02 |
库尔纳公司 |
通过抑制集落刺激因子3(csf3)的天然反义转录物而治疗csf3相关疾病
|
US9044494B2
(en)
|
2010-04-09 |
2015-06-02 |
Curna, Inc. |
Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
|
JP6005628B2
(ja)
|
2010-04-28 |
2016-10-12 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物
|
KR101915115B1
(ko)
|
2010-05-03 |
2018-11-05 |
큐알엔에이, 인크. |
시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
|
TWI586356B
(zh)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
NO2576783T3
(de)
|
2010-05-26 |
2018-04-28 |
|
|
CN102971423B
(zh)
|
2010-05-26 |
2018-01-26 |
库尔纳公司 |
通过抑制蛋氨酸硫氧化物还原酶a(msra)的天然反义转录物而治疗msra相关疾病
|
WO2011156278A1
(en)
|
2010-06-07 |
2011-12-15 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
PT2585596T
(pt)
|
2010-06-23 |
2021-03-23 |
Curna Inc |
Tratamento de doenças relacionadas com a subunidade alfa de canais de sódio dependentes de voltagem (scna) por inibição da transcrição antissentido natural para scna
|
JP5998131B2
(ja)
|
2010-07-14 |
2016-09-28 |
カッパーアールエヌエー,インコーポレイテッド |
Discslargehomolog(dlg)dlg1への天然アンチセンス転写物の阻害によるdlg関連疾患の治療
|
EP2412724A1
(de)
|
2010-07-29 |
2012-02-01 |
Centre National de la Recherche Scientifique (C.N.R.S) |
Regulierung der Glypican-4-Aktivität zur Modulierung des Schicksals von Stammzellen und Verwendungen davon
|
ES2640755T3
(es)
|
2010-10-06 |
2017-11-06 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la Sialidasa 4 (neu4) mediante inhibición del transcrito antisentido natural al gen neu4
|
RU2597972C2
(ru)
|
2010-10-22 |
2016-09-20 |
Курна Инк. |
Лечение заболеваний, связанных с геном альфа-l-идуронидазы (idua), путем ингибирования природного антисмыслового транскрипта гена idua
|
WO2012068340A2
(en)
|
2010-11-18 |
2012-05-24 |
Opko Curna Llc |
Antagonat compositions and methods of use
|
WO2012071238A2
(en)
|
2010-11-23 |
2012-05-31 |
Opko Curna Llc |
Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
|
ES2664992T3
(es)
|
2010-12-02 |
2018-04-24 |
Daiichi Sankyo Company, Limited |
Polinucleótido monocatenario modificado
|
EP3067421B1
(de)
|
2011-02-08 |
2018-10-10 |
Ionis Pharmaceuticals, Inc. |
Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
|
SG10201604479YA
(en)
|
2011-03-03 |
2016-07-28 |
Quark Pharmaceuticals Inc |
Oligonucleotide Modulators Of The Toll-Like Receptor Pathway
|
CA2828002A1
(en)
|
2011-03-03 |
2012-09-07 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treating lung disease and injury
|
US9796979B2
(en)
|
2011-03-03 |
2017-10-24 |
Quark Pharmaceuticals Inc. |
Oligonucleotide modulators of the toll-like receptor pathway
|
TWI658830B
(zh)
|
2011-06-08 |
2019-05-11 |
日東電工股份有限公司 |
Hsp47表現調控強化用類視色素脂質體
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
WO2012170771A1
(en)
|
2011-06-09 |
2012-12-13 |
Curna, Inc. |
Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
|
UY34128A
(es)
|
2011-06-15 |
2013-01-31 |
Grifols Therapeutics Inc |
Métodos, composiciones y kits para determinar el virus de la inmunodeficiencia humana (vih)?.
|
DK2742135T4
(da)
|
2011-08-11 |
2020-07-13 |
Ionis Pharmaceuticals Inc |
Bindingsmodificerede gapped oligomeriske forbindelser og anvendelser deraf
|
CN103874486A
(zh)
|
2011-09-06 |
2014-06-18 |
库尔纳公司 |
用小分子治疗与电压门控钠通道的α亚基(SCNxA)相关的疾病
|
EP2756080B1
(de)
|
2011-09-14 |
2019-02-20 |
Translate Bio MA, Inc. |
Multimere oligonukleotidverbindungen
|
AU2012332517B9
(en)
|
2011-11-03 |
2017-08-10 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for neuroprotection
|
US10557136B2
(en)
|
2011-12-12 |
2020-02-11 |
Oncolmmunin Inc. |
In vivo delivery of oligonucleotides
|
US9737480B2
(en)
|
2012-02-06 |
2017-08-22 |
President And Fellows Of Harvard College |
ARRDC1-mediated microvesicles (ARMMs) and uses thereof
|
US20150031750A1
(en)
|
2012-03-15 |
2015-01-29 |
The Scripps Research Institute |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
EP2831231A1
(de)
|
2012-03-30 |
2015-02-04 |
Isis Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur modulation der tau-expression zur verringerung von anfällen und modifizierung eines neurodegenerativen syndroms
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
EP2850092B1
(de)
|
2012-04-09 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Tricyclische nukleinsäureanaloga
|
US9914922B2
(en)
|
2012-04-20 |
2018-03-13 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
WO2013173608A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating mecp2 expression
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
EP2850189B8
(de)
|
2012-05-16 |
2019-01-23 |
Translate Bio MA, Inc. |
Zusammensetzungen und verfahren zur modulation von genexpression
|
KR20150030205A
(ko)
|
2012-05-16 |
2015-03-19 |
라나 테라퓨틱스, 인크. |
Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법
|
JP2013256452A
(ja)
*
|
2012-06-11 |
2013-12-26 |
Kawaken Fine Chem Co Ltd |
メラニン産生抑制剤とその組成物
|
ES2798301T3
(es)
*
|
2012-06-18 |
2020-12-10 |
Daiichi Sankyo Co Ltd |
Intermedio para producción de análogos de nucleósidos, y procedimiento para su producción
|
EP2897633B1
(de)
|
2012-09-18 |
2020-01-01 |
UTI Limited Partnership |
Behandlung von schmerzen durch hemmung von usp5-deubiquitinase
|
WO2014059353A2
(en)
|
2012-10-11 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
KR20150087270A
(ko)
|
2012-11-05 |
2015-07-29 |
프로나이 테라퓨틱스, 인코포레이티드 |
Bcl2 발현 조절에 의한 암치료용 바이오마커 이용 방법
|
EP2961853B1
(de)
|
2013-02-28 |
2018-09-19 |
The Board of Regents of The University of Texas System |
Verfahren zur klassifizierung einer krebserkrankung als anfälligkeit für tmepai-gerichtete therapien und zur heilung solcher krebserkrankungen
|
WO2014143158A1
(en)
|
2013-03-13 |
2014-09-18 |
The Broad Institute, Inc. |
Compositions and methods for labeling of agents
|
CN105264091B
(zh)
|
2013-03-14 |
2020-02-28 |
Ionis制药公司 |
用于调节tau表达的组合物和方法
|
US9273349B2
(en)
|
2013-03-14 |
2016-03-01 |
Affymetrix, Inc. |
Detection of nucleic acids
|
EP2992112B1
(de)
|
2013-04-22 |
2020-06-03 |
Icahn School of Medicine at Mount Sinai |
Mutationen in pdgfrb und notch3 als ursachen für autosomale dominante infantile myofibromatose
|
CA2921514C
(en)
|
2013-05-01 |
2023-10-24 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating apolipoprotein c-iii expression
|
TWI702046B
(zh)
|
2013-07-19 |
2020-08-21 |
美商Ionis製藥公司 |
用於調節τ蛋白表現之組合物
|
WO2015051283A1
(en)
|
2013-10-04 |
2015-04-09 |
Rana Therapeutics, Inc. |
Compositions and methods for treating amyotrophic lateral sclerosis
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
WO2015075166A1
(en)
|
2013-11-22 |
2015-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of a bacterial infection
|
RU2744194C2
(ru)
|
2013-12-02 |
2021-03-03 |
Фио Фармасьютикалс Корп |
Иммунотерапия рака
|
WO2015118407A2
(en)
|
2014-01-29 |
2015-08-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Oligonucleotides and methods for inhibiting or reducing bacterial biofilms
|
CN106459972B
(zh)
|
2014-04-01 |
2020-05-08 |
比奥根Ma公司 |
用于调节sod-1表达的组合物
|
EP3137476B1
(de)
|
2014-04-28 |
2019-10-09 |
Ionis Pharmaceuticals, Inc. |
Verbindungsmodifizierte oligomerverbindungen
|
EP3137119B1
(de)
|
2014-04-28 |
2020-07-01 |
Phio Pharmaceuticals Corp. |
Verfahren zur behandlung von krebs mithilfe von einer nukleinsaüre gegen mdm2
|
PT3137596T
(pt)
|
2014-05-01 |
2019-09-27 |
Ionis Pharmaceuticals Inc |
Composições e métodos para modulação da expressão do factor b do complemento
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α-1抗胰蛋白酶基因表現之組合物及方法
|
JP6562517B2
(ja)
*
|
2014-07-31 |
2019-08-21 |
国立大学法人大阪大学 |
架橋型ヌクレオシドおよびヌクレオチド
|
IL234246A0
(en)
|
2014-08-21 |
2014-11-30 |
Omrix Biopharmaceuticals Ltd |
Stabilized thrombin
|
EP3188799B1
(de)
|
2014-09-05 |
2022-07-06 |
Phio Pharmaceuticals Corp. |
Verfahren zur behandlung von alterung und hauterkrankungen mit auf tyr oder mmp1 gerichteten nukleinsäuren
|
EP3201339A4
(de)
|
2014-10-03 |
2018-09-19 |
Cold Spring Harbor Laboratory |
Gezielten erhöhung der nukleären genleistung
|
US9816080B2
(en)
|
2014-10-31 |
2017-11-14 |
President And Fellows Of Harvard College |
Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
|
EP3234141A4
(de)
|
2014-12-18 |
2018-06-20 |
Alnylam Pharmaceuticals, Inc. |
Reversir-tm-verbindungen
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
US10407678B2
(en)
|
2015-04-16 |
2019-09-10 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
EP3862005A1
(de)
|
2015-07-06 |
2021-08-11 |
Phio Pharmaceuticals Corp. |
Gegen superoxid-dismutase 1 (sod1) gerichtete nukleinsäuremoleküle
|
CA2989970A1
(en)
|
2015-07-17 |
2017-01-26 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
CN107922945A
(zh)
|
2015-08-24 |
2018-04-17 |
罗氏创新中心哥本哈根有限公司 |
Lna‑g 方法
|
WO2017060731A1
(en)
|
2015-10-09 |
2017-04-13 |
University Of Southampton |
Modulation of gene expression and screening for deregulated protein expression
|
CN109563509B
(zh)
|
2015-10-19 |
2022-08-09 |
菲奥医药公司 |
靶向长非编码rna的减小尺寸的自递送核酸化合物
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
WO2017079442A1
(en)
|
2015-11-04 |
2017-05-11 |
Icahn School Of Medicine At Mount Sinai |
Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
|
EP3374509B1
(de)
|
2015-11-12 |
2020-12-16 |
H. Hoffnabb-La Roche Ag |
Oligonukleotide zur induktion der paternalen ube3a-expression
|
US11058709B1
(en)
|
2015-12-04 |
2021-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
EP3390636B1
(de)
|
2015-12-14 |
2021-05-19 |
Cold Spring Harbor Laboratory |
Antisense-oligomere zur behandlung von dravet-syndrom
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
JP6748219B2
(ja)
|
2016-03-14 |
2020-08-26 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Pd−l1発現低減用のオリゴヌクレオチド
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
WO2017161172A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating keap1
|
US11248019B2
(en)
|
2016-04-14 |
2022-02-15 |
Hoffmann-La Roche Inc. |
Trityl-mono-GalNAc compounds and their use
|
EP3448881B1
(de)
|
2016-04-26 |
2023-06-07 |
Icahn School of Medicine at Mount Sinai |
Behandlung von hippo-pfad-mutanten tumoren und verfahren zur identifizierung von probanden als kandidaten für die behandlung
|
EP3471781A4
(de)
|
2016-06-17 |
2020-05-06 |
Ionis Pharmaceuticals, Inc. |
Modulierung der gys1-expression
|
MA45496A
(fr)
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
SG10202005885VA
(en)
|
2016-07-01 |
2020-07-29 |
Hoffmann La Roche |
Antisense oligonucleotides for modulating htra1 expression
|
EP3507367A4
(de)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
Cyclisches dinukleotidverbindungen mit eingeschlossenen nukleinsäuren und verwendungen davon
|
WO2018013525A1
(en)
|
2016-07-11 |
2018-01-18 |
Translate Bio Ma, Inc. |
Nucleic acid conjugates and uses thereof
|
JP6970187B2
(ja)
|
2016-09-14 |
2021-11-24 |
ヤンセン バイオファーマ インク. |
修飾オリゴヌクレオチド及び使用方法
|
JOP20190065A1
(ar)
|
2016-09-29 |
2019-03-28 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن tau
|
US11730823B2
(en)
|
2016-10-03 |
2023-08-22 |
President And Fellows Of Harvard College |
Delivery of therapeutic RNAs via ARRDC1-mediated microvesicles
|
EP3538671A1
(de)
|
2016-11-11 |
2019-09-18 |
Roche Innovation Center Copenhagen A/S |
Erfassung und erkennung therapeutischer oligonukleotide
|
WO2018102745A1
(en)
|
2016-12-02 |
2018-06-07 |
Cold Spring Harbor Laboratory |
Modulation of lnc05 expression
|
AU2017386771A1
(en)
|
2016-12-28 |
2019-06-20 |
Daiichi Sankyo Company, Limited |
Therapeutic drug for Alport's syndrome
|
CN110268060A
(zh)
|
2017-01-10 |
2019-09-20 |
箭头药业股份有限公司 |
α-1抗胰蛋白酶(AAT)RNAi物质、包含AAT RNAi物质的组合物和使用方法
|
WO2018130585A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating relb expression
|
US20200216845A1
(en)
|
2017-01-13 |
2020-07-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rela expression
|
WO2018130584A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb2 expression
|
US20190338286A1
(en)
|
2017-01-13 |
2019-11-07 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rel expression
|
WO2018130583A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb1 expression
|
WO2018165564A1
(en)
|
2017-03-09 |
2018-09-13 |
Ionis Pharmaceuticals, Inc. |
Morpholino modified oligomeric compounds
|
CA3055932A1
(en)
|
2017-03-10 |
2018-09-13 |
Lakewood Amedex, Inc. |
Antimicrobial compounds, compositions, and uses thereof
|
US11377468B2
(en)
|
2017-03-10 |
2022-07-05 |
Lakewood Amedex, Inc. |
Antimicrobial compounds, compositions, and uses thereof
|
US11963974B2
(en)
|
2017-03-10 |
2024-04-23 |
National Center For Child Health And Development |
Antisense oligonucleotide and composition for prevention or treatment of glycogen storage disease type Ia
|
US11795192B2
(en)
|
2017-03-10 |
2023-10-24 |
Lakewood Amedex, Inc. |
Antimicrobial compounds, compositions, and uses thereof
|
JP7306653B2
(ja)
|
2017-03-17 |
2023-07-11 |
国立大学法人千葉大学 |
構造強化されたS-TuDを用いた新規がん治療法
|
JP7246729B2
(ja)
|
2017-05-18 |
2023-03-28 |
国立大学法人京都大学 |
脊髄小脳変性症36型の予防又は治療用組成物
|
US20190055564A1
(en)
|
2017-06-01 |
2019-02-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
US20200172903A1
(en)
|
2017-07-05 |
2020-06-04 |
Osaka University |
ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSION
|
JP7307417B2
(ja)
|
2017-07-10 |
2023-07-12 |
国立大学法人大阪大学 |
Tdp-43の発現量を調節するアンチセンスオリゴヌクレオチド及びその用途
|
WO2019030313A2
(en)
|
2017-08-11 |
2019-02-14 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
|
WO2019036613A1
(en)
|
2017-08-18 |
2019-02-21 |
Ionis Pharmaceuticals, Inc. |
MODULATION OF THE NOTCH SIGNALING PATHWAY FOR THE TREATMENT OF RESPIRATORY DISORDERS
|
WO2019038228A1
(en)
|
2017-08-22 |
2019-02-28 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
|
GB2582457B
(en)
|
2017-08-25 |
2021-02-24 |
Stoke Therapeutics Inc |
Antisense oligomers specific for SCN1A
|
US10517889B2
(en)
|
2017-09-08 |
2019-12-31 |
Ionis Pharmaceuticals, Inc. |
Modulators of SMAD7 expression
|
KR20200100601A
(ko)
|
2017-09-14 |
2020-08-26 |
얀센 바이오파마, 인크. |
GalNAc 유도체
|
JP2021502059A
(ja)
|
2017-10-13 |
2021-01-28 |
ロシュ イノベーション センター コペンハーゲン エーエス |
部分的に立体定義されたオリゴヌクレオチドのサブライブラリーを使用することによる、アンチセンスオリゴヌクレオチドの、改良された立体定義されたホスホロチオエートオリゴヌクレオチド変異体を同定するための方法
|
IL272566B1
(en)
|
2017-10-16 |
2024-03-01 |
Hoffmann La Roche |
Nucleic acid molecule to reduce papd5 and papd7 mRNA to treat hepatitis b infection
|
EP3697904A1
(de)
|
2017-10-17 |
2020-08-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Kombinationsbehandlung für zystische fibrose
|
WO2019111791A1
(ja)
*
|
2017-12-07 |
2019-06-13 |
第一三共株式会社 |
ジストロフィン遺伝子のイントロンリテンションを解消するアンチセンスオリゴヌクレオチド
|
WO2019115416A2
(en)
|
2017-12-11 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating fndc3b expression
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
MX2020005872A
(es)
|
2017-12-21 |
2020-08-13 |
Hoffmann La Roche |
Diagnostico complementario para antagonistas de acido ribonucleico (arn) de proteina a1 de alto requerimiento de temperatura a (htra1).
|
AU2018386527A1
(en)
|
2017-12-22 |
2020-04-30 |
Roche Innovation Center Copenhagen A/S |
Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
JP7476102B2
(ja)
|
2017-12-22 |
2024-04-30 |
ロシュ イノベーション センター コペンハーゲン エーエス |
ホスホロジチオアートヌクレオシド間結合を含むオリゴヌクレオチド
|
EP4092118A1
(de)
|
2017-12-22 |
2022-11-23 |
Roche Innovation Center Copenhagen A/S |
Neuartige thiophosphoramidite
|
CN111699258A
(zh)
|
2018-01-10 |
2020-09-22 |
哥本哈根罗氏创新中心 |
用于调控pias4表达的寡核苷酸
|
PE20210172A1
(es)
|
2018-01-12 |
2021-01-29 |
Roche Innovation Ct Copenhagen As |
Oligonucleotidos antisentido para alfa-sinucleina y usos de los mismos
|
JP2021510295A
(ja)
|
2018-01-12 |
2021-04-22 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Gsk3b発現を調節するためのオリゴヌクレオチド
|
KR20200140240A
(ko)
|
2018-01-12 |
2020-12-15 |
브리스톨-마이어스 스큅 컴퍼니 |
알파-시누클레인을 표적화하는 안티센스 올리고뉴클레오티드 및 그의 용도
|
WO2019140231A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
US20210095276A1
(en)
|
2018-01-17 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating erc1 expression
|
CN111655851A
(zh)
|
2018-01-18 |
2020-09-11 |
哥本哈根罗氏创新中心 |
靶向srebp1的反义寡核苷酸
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
JP7281474B2
(ja)
|
2018-02-09 |
2023-05-25 |
ジェネンテック, インコーポレイテッド |
Tmem106b発現を調節するためのオリゴヌクレオチド
|
SG11202007652UA
(en)
|
2018-02-21 |
2020-09-29 |
Bristol Myers Squibb Co |
Camk2d antisense oligonucleotides and uses thereof
|
CN115976028A
(zh)
|
2018-03-09 |
2023-04-18 |
第一三共株式会社 |
糖原病Ia型治疗药
|
US11453881B2
(en)
|
2018-03-13 |
2022-09-27 |
Janssen Pharmaceutica Nv |
Modified oligonucleotides for use in treatment of tauopathies
|
KR20200140853A
(ko)
|
2018-04-05 |
2020-12-16 |
에프. 호프만-라 로슈 아게 |
B형 간염 바이러스 감염을 치료하기 위한 fubp1 억제제의 용도
|
US20210071247A1
(en)
|
2018-05-07 |
2021-03-11 |
Roche Innovation Center Copenhagen A/S |
Massively parallel discovery methods for oligonucleotide therapeutics
|
KR20210018267A
(ko)
|
2018-05-07 |
2021-02-17 |
알닐람 파마슈티칼스 인코포레이티드 |
간외 전달
|
US20210371860A1
(en)
|
2018-05-08 |
2021-12-02 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
EP3793685A1
(de)
|
2018-05-18 |
2021-03-24 |
F. Hoffmann-La Roche AG |
Pharmazeutische zusammensetzungen zur behandlung von krankheiten im zusammenhang mit mikro-rna
|
WO2019224172A1
(en)
|
2018-05-25 |
2019-11-28 |
Roche Innovation Center Copenhagen A/S |
Novel process for making allofuranose from glucofuranose
|
CN112912500A
(zh)
|
2018-06-05 |
2021-06-04 |
豪夫迈·罗氏有限公司 |
用于调节atxn2表达的寡核苷酸
|
CN112218950A
(zh)
|
2018-06-13 |
2021-01-12 |
第一三共株式会社 |
心肌损伤治疗药
|
WO2019246112A1
(en)
|
2018-06-18 |
2019-12-26 |
University Of Rochester |
Methods of treating schizophrenia and other neuropsychiatric disorders
|
WO2019246262A2
(en)
|
2018-06-21 |
2019-12-26 |
University Of Rochester |
Methods of treating or inhibiting onset of huntington's disease
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
EP3818159A1
(de)
|
2018-07-03 |
2021-05-12 |
F. Hoffmann-La Roche AG |
Oligonukleotide zur modulation der tau-expression
|
CN112469827A
(zh)
|
2018-07-04 |
2021-03-09 |
国立大学法人东海国立大学机构 |
控制Tau的剪接的反义寡核苷酸及其用途
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
MX2021000404A
(es)
|
2018-07-13 |
2021-03-25 |
Hoffmann La Roche |
Oligonucleotidos para modular la expresion de rtel1.
|
TW202020155A
(zh)
|
2018-07-31 |
2020-06-01 |
丹麥商羅氏創新中心哥本哈根有限公司 |
含有三硫代磷酸酯核苷間連結之寡核苷酸
|
CN112236439A
(zh)
|
2018-07-31 |
2021-01-15 |
罗氏创新中心哥本哈根有限公司 |
包含三硫代磷酸酯核苷间键的寡核苷酸
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
JP2021534759A
(ja)
|
2018-08-23 |
2021-12-16 |
ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S |
Microrna−134バイオマーカー
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
CN113728102A
(zh)
|
2018-08-28 |
2021-11-30 |
罗氏创新中心哥本哈根有限公司 |
使用剪接调节化合物进行新抗原工程化
|
EP3620519A1
(de)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Verwendung von isolierten extrazellulären vesikeln aus milch zur oralen verabreichung von oligonukleotiden
|
EP3856907A1
(de)
|
2018-09-28 |
2021-08-04 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr)-irna-zusammensetzungen und verfahren zur verwendung davon für die behandlung oder prävention ttr-assoziierter augenerkrankungen
|
SG11202103180QA
(en)
|
2018-10-17 |
2021-05-28 |
Lakewood Amedex Inc |
Methods and compositions for treating oral mucositis
|
JP2022512877A
(ja)
|
2018-11-01 |
2022-02-07 |
エフ.ホフマン-ラ ロシュ アーゲー |
Tia1を標的とするアンチセンスオリゴヌクレオチド
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
TW202039840A
(zh)
|
2018-11-15 |
2020-11-01 |
美商伊奧尼斯醫藥公司 |
Irf5表現調節劑
|
EP3883941A1
(de)
|
2018-11-22 |
2021-09-29 |
Roche Innovation Center Copenhagen A/S |
Pyridiniumsalze als aktivatoren bei der synthese von stereodefinierten oligonukleotiden
|
WO2020109343A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Combination therapy for treatment of macular degeneration
|
WO2020109344A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Occular administration device for antisense oligonucleotides
|
AU2019396450A1
(en)
|
2018-12-11 |
2021-06-24 |
University Of Rochester |
Methods of treating schizophrenia and other neuropsychiatric disorders
|
EP3898975A2
(de)
|
2018-12-21 |
2021-10-27 |
Boehringer Ingelheim International GmbH |
Gegen card9 gerichtete antisense-oligonukleotide
|
EP3914232A1
(de)
|
2019-01-25 |
2021-12-01 |
F. Hoffmann-La Roche AG |
Lipidvesikel zur oralen wirkstoffverabreichung
|
BR112021013369A2
(pt)
|
2019-01-31 |
2021-09-21 |
Ionis Pharmaceuticals, Inc. |
Moduladores de expressão de yap1
|
US20230057355A1
(en)
|
2019-02-13 |
2023-02-23 |
University Of Rochester |
Gene networks that mediate remyelination of the human brain
|
CA3130431A1
(en)
|
2019-02-20 |
2020-08-27 |
Roche Innovation Center Copenhagen A/S |
Phosphonoacetate gapmer oligonucleotides
|
CA3129646A1
(en)
|
2019-02-20 |
2020-08-27 |
Roche Innovation Center Copenhagen A/S |
Novel phosphoramidites
|
CN113474633A
(zh)
|
2019-02-26 |
2021-10-01 |
罗氏创新中心哥本哈根有限公司 |
寡核苷酸配制方法
|
US11279932B2
(en)
|
2019-02-27 |
2022-03-22 |
Ionis Pharmaceuticals, Inc. |
Modulators of MALAT1 expression
|
EP3934695A1
(de)
|
2019-03-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Intrazelluläres molekül-targeting
|
US20240108747A1
(en)
|
2019-03-21 |
2024-04-04 |
Lonza Sales Ag |
Extracellular vesicle conjugates and uses thereof
|
EP3967328A4
(de)
|
2019-03-29 |
2022-12-28 |
Sysmex Corporation |
Neue künstliche nukleinsäure, verfahren zu ihrer herstellung und ihre verwendung
|
SG11202110745VA
(en)
|
2019-04-03 |
2021-10-28 |
Bristol Myers Squibb Co |
Angptl2 antisense oligonucleotides and uses thereof
|
EP3947677A1
(de)
|
2019-04-04 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Oligonukleotide zur modulierung der atxn2-expression
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
US20220194976A1
(en)
|
2019-04-16 |
2022-06-23 |
Roche Innovation Center Copenhagen A/S |
Novel Process for Preparing Nucleotide P(V) Monomers
|
WO2020221705A1
(en)
|
2019-04-30 |
2020-11-05 |
Roche Innovation Center Copenhagen A/S |
Novel process for preparing rhenium chelated mag3 oligonucleotides
|
JP2022530678A
(ja)
|
2019-05-03 |
2022-06-30 |
ディセルナ ファーマシューティカルズ インコーポレイテッド |
短縮センス鎖を有する二本鎖核酸阻害剤分子
|
CA3138915A1
(en)
|
2019-05-17 |
2020-11-26 |
Alnylam Pharmaceuticals, Inc. |
Oral delivery of oligonucleotides
|
EP3980539A1
(de)
|
2019-06-06 |
2022-04-13 |
F. Hoffmann-La Roche AG |
Gegen atxn3 gerichtete antisense-oligonukleotide
|
US20220315617A1
(en)
*
|
2019-06-19 |
2022-10-06 |
Yamasa Corporation |
Crosslinked Nucleoside Intermediate Crystal And Method For Producing Same, And Method For Producing Crosslinked Nucleoside Amidite
|
EP3995153A4
(de)
|
2019-06-26 |
2023-11-22 |
KNC Laboratories Co., Ltd. |
Nukleinsäurearzneimittel zur unterdrückung der produktion von myostatin-mrna
|
EP3997225A1
(de)
|
2019-07-10 |
2022-05-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur behandlung von epilepsie
|
BR112021024764A2
(pt)
|
2019-07-12 |
2022-04-19 |
Daiichi Sankyo Co Ltd |
Oligonucleotídeo antissenso capaz de alterar o splicing de pré-mrna de dux4
|
JP2022541502A
(ja)
|
2019-07-18 |
2022-09-26 |
ユニバーシティー オブ ロチェスター |
細胞の細胞型選択的免疫保護
|
WO2021021673A1
(en)
|
2019-07-26 |
2021-02-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
JP2022544934A
(ja)
|
2019-08-14 |
2022-10-24 |
コディアック バイオサイエンシーズ, インコーポレイテッド |
Stat3-アンチセンスオリゴヌクレオチドを含む細胞外小胞
|
WO2021030781A1
(en)
|
2019-08-14 |
2021-02-18 |
Codiak Biosciences, Inc. |
Extracellular vesicles with antisense oligonucleotides targeting kras
|
CA3147680A1
(en)
|
2019-08-14 |
2021-02-18 |
Dalia BURZYN |
Extracellular vesicle-aso constructs targeting stat6
|
JP2022550248A
(ja)
|
2019-08-14 |
2022-12-01 |
コディアック バイオサイエンシーズ, インコーポレイテッド |
分子に連結された細胞外小胞及びその使用
|
US20230132093A1
(en)
|
2019-08-14 |
2023-04-27 |
Codiak Biosciences, Inc. |
Extracellular vesicle-nlrp3 antagonist
|
WO2021030780A1
(en)
|
2019-08-14 |
2021-02-18 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting cebp/beta
|
WO2021030778A1
(en)
|
2019-08-15 |
2021-02-18 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds and uses thereof
|
AU2020345317A1
(en)
|
2019-09-10 |
2022-04-21 |
Daiichi Sankyo Company, Limited |
CONJUGATE OF GalNAc-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF
|
WO2021062058A1
(en)
|
2019-09-25 |
2021-04-01 |
Codiak Biosciences, Inc. |
Sting agonist comprising exosomes for treating neuroimmunological disorders
|
WO2021074657A1
(en)
|
2019-10-17 |
2021-04-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination treatment for cystic fibrosis
|
US20230348522A1
(en)
|
2019-10-18 |
2023-11-02 |
Daiichi Sankyo Company, Limited |
Method for producing bicyclic phosphoramidite
|
CN111109591A
(zh)
|
2019-10-25 |
2020-05-08 |
新疆红旗坡农业发展集团有限公司 |
肠道微生态高效重建型苹果酵素及加工技术
|
AU2020378414A1
(en)
|
2019-11-06 |
2022-05-26 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery
|
WO2021092145A1
(en)
|
2019-11-06 |
2021-05-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
US20230016983A1
(en)
|
2019-11-19 |
2023-01-19 |
lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
Antisense oligonucleotides and thier use for the treatment of cancer
|
JP2023506547A
(ja)
|
2019-12-19 |
2023-02-16 |
エフ. ホフマン-ラ ロシュ エージー. |
B型肝炎ウイルス感染を処置するためのcops3阻害剤の使用
|
JP2023506540A
(ja)
|
2019-12-19 |
2023-02-16 |
エフ. ホフマン-ラ ロシュ エージー. |
B型肝炎ウイルス感染を処置するためのscamp3阻害剤の使用
|
WO2021122735A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of sept9 inhibitors for treating hepatitis b virus infection
|
EP4077671A1
(de)
|
2019-12-19 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Verwendung von saraf-inhibitoren zum behandeln von hepatitis-b-virus-infektionen
|
WO2021122910A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of sbds inhibitors for treating hepatitis b virus infection
|
CN114829603A
(zh)
|
2019-12-20 |
2022-07-29 |
豪夫迈·罗氏有限公司 |
用于抑制scn9a表达的增强寡核苷酸
|
CN114828852A
(zh)
|
2019-12-24 |
2022-07-29 |
豪夫迈·罗氏有限公司 |
用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合
|
TW202137987A
(zh)
|
2019-12-24 |
2021-10-16 |
瑞士商赫孚孟拉羅股份公司 |
用於治療hbv之靶向hbv的治療性寡核苷酸及tlr7促效劑之醫藥組合
|
WO2021158810A1
(en)
|
2020-02-05 |
2021-08-12 |
Bristol-Myers Squibb Company |
Oligonucleotides for splice modulation of camk2d
|
WO2021170697A1
(en)
|
2020-02-28 |
2021-09-02 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating cd73 exon 7 splicing
|
CA3175125A1
(en)
|
2020-03-11 |
2021-09-16 |
Biocomber Co., Ltd. |
Single-stranded nucleic acid molecule for inducing -1 frameshift and composition
|
WO2021184020A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Methods of treating neuroinflammation
|
WO2021184021A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting pmp22
|
AU2021247043A1
(en)
|
2020-03-31 |
2022-10-27 |
Janssen Biopharma, Inc. |
Synthesis of oligonucleotides and related compounds
|
WO2021231210A1
(en)
|
2020-05-11 |
2021-11-18 |
Genentech, Inc. |
Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
|
JP2023527684A
(ja)
|
2020-05-11 |
2023-06-30 |
ジェネンテック, インコーポレイテッド |
神経疾患を治療するための補体成分c1s阻害剤、並びにそれを使用する関連組成物、システム及び方法
|
CN115867657A
(zh)
|
2020-05-11 |
2023-03-28 |
斯托克制药公司 |
用于治疗疾患和疾病的opa1反义寡聚物
|
CN115698290A
(zh)
|
2020-05-11 |
2023-02-03 |
基因泰克公司 |
用于治疗神经系统疾病的补体组分4抑制剂以及使用它们的相关组合物、系统和方法
|
JP2023526267A
(ja)
|
2020-05-13 |
2023-06-21 |
エフ. ホフマン-ラ ロシュ アーゲー |
プログラニュリン標的オリゴヌクレオチドアゴニスト
|
US20230193269A1
(en)
|
2020-05-22 |
2023-06-22 |
Boehringer Ingelheim International Gmbh |
Oligonucleotides for splice modulation of card9
|
CN115702243A
(zh)
|
2020-06-09 |
2023-02-14 |
罗氏创新中心哥本哈根有限公司 |
用于治疗性多核苷酸的鸟苷类似物
|
AR122731A1
(es)
|
2020-06-26 |
2022-10-05 |
Hoffmann La Roche |
Oligonucleótidos mejorados para modular la expresión de fubp1
|
EP4179091A1
(de)
|
2020-07-10 |
2023-05-17 |
Institut National De La Sante Et De La Recherche Medicale - Inserm |
Verfahren und zusammensetzungen zur behandlung von epilepsie
|
WO2022018155A1
(en)
|
2020-07-23 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotides for splice modulation of stmn2
|
JP2023534557A
(ja)
|
2020-07-23 |
2023-08-09 |
エフ. ホフマン-ラ ロシュ アーゲー |
Rna結合タンパク質部位を標的とするオリゴヌクレオチド
|
EP4201484A1
(de)
|
2020-07-28 |
2023-06-28 |
KNC Laboratories Co., Ltd. |
Antisense-nukleinsäure zur induktion von exon-skipping des angiotensin-konvertierenden enzym-2-gens
|
JP2023538630A
(ja)
|
2020-08-21 |
2023-09-08 |
エフ. ホフマン-ラ ロシュ アーゲー |
B型肝炎ウイルス感染症を処置するためのa1cf阻害剤の使用
|
WO2022043531A1
(en)
*
|
2020-08-28 |
2022-03-03 |
Janssen Sciences Ireland Unlimited Company |
7'-substituted 2'-o-4'-c-ethylene-bridged nucleic acid (ena) monomers and uses thereof
|
JPWO2022065413A1
(de)
|
2020-09-25 |
2022-03-31 |
|
|
US20230364127A1
(en)
|
2020-10-06 |
2023-11-16 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting stat6
|
TW202237843A
(zh)
|
2020-12-03 |
2022-10-01 |
瑞士商赫孚孟拉羅股份公司 |
靶向atxn3之反義寡核苷酸
|
AR124229A1
(es)
|
2020-12-03 |
2023-03-01 |
Hoffmann La Roche |
Oligonucleótidos antisentido que actúan sobre atxn3
|
WO2022122613A1
(en)
|
2020-12-08 |
2022-06-16 |
F. Hoffmann-La Roche Ag |
Novel synthesis of phosphorodithioate oligonucleotides
|
AR124378A1
(es)
|
2020-12-18 |
2023-03-22 |
Hoffmann La Roche |
Oligonucleótidos antisentido dirigida a progranulina
|
WO2022136140A1
(en)
|
2020-12-22 |
2022-06-30 |
F. Hoffmann-La Roche Ag |
Oligonucleotides targeting xbp1
|
KR20230128050A
(ko)
*
|
2020-12-31 |
2023-09-01 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 근긴장성 이영양증을 치료하기위한 그의 용도
|
AU2021411579A1
(en)
|
2020-12-31 |
2023-07-13 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
WO2022147223A2
(en)
|
2020-12-31 |
2022-07-07 |
Alnylam Pharmaceuticals, Inc. |
2'-modified nucleoside based oligonucleotide prodrugs
|
TW202246500A
(zh)
|
2021-02-02 |
2022-12-01 |
瑞士商赫孚孟拉羅股份公司 |
用於抑制 rtel1 表現之增強型寡核苷酸
|
WO2022178149A2
(en)
|
2021-02-17 |
2022-08-25 |
Codiak Biosciences, Inc. |
Extracellular vesicle-nlrp3 antagonist
|
CN117377499A
(zh)
|
2021-02-17 |
2024-01-09 |
隆萨销售股份有限公司 |
经由优化的接头和锚定部分与生物活性分子连接的细胞外囊泡
|
CN116981772A
(zh)
|
2021-02-26 |
2023-10-31 |
神户天然物化学株式会社 |
表达肌抑素的剪接变体的核酸药物
|
KR20240009393A
(ko)
|
2021-03-31 |
2024-01-22 |
엔트라다 테라퓨틱스, 인크. |
사이클릭 세포 침투 펩티드
|
WO2022212884A1
(en)
|
2021-04-01 |
2022-10-06 |
Codiak Biosciences, Inc. |
Extracellular vesicle compositions
|
CA3217463A1
(en)
|
2021-05-10 |
2022-11-17 |
Ziqing QIAN |
Compositions and methods for modulating mrna splicing
|
IL308353A
(en)
|
2021-05-10 |
2024-01-01 |
Entrada Therapeutics Inc |
Compositions and methods for modulating tissue distribution of intracellular therapies
|
EP4337263A1
(de)
|
2021-05-10 |
2024-03-20 |
Entrada Therapeutics, Inc. |
Zusammensetzungen und verfahren zur modulation der interferon-regulatorischen faktor-5 (irf-5)-aktivität
|
AU2022288115A1
(en)
|
2021-06-08 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Oligonucleotide progranulin agonists
|
IL309001A
(en)
|
2021-06-23 |
2024-02-01 |
Entrada Therapeutics Inc |
Antisense compounds and methods for targeting CUG repeats
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
KR20240036041A
(ko)
|
2021-07-21 |
2024-03-19 |
알닐람 파마슈티칼스 인코포레이티드 |
대사 장애-연관 표적 유전자 iRNA 조성물 및 이의 사용 방법
|
CA3229305A1
(en)
|
2021-08-16 |
2023-02-23 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
WO2023026994A1
(ja)
|
2021-08-21 |
2023-03-02 |
武田薬品工業株式会社 |
ヒトトランスフェリンレセプター結合ペプチド-薬物コンジュゲート
|
WO2023034817A1
(en)
|
2021-09-01 |
2023-03-09 |
Entrada Therapeutics, Inc. |
Compounds and methods for skipping exon 44 in duchenne muscular dystrophy
|
WO2023052317A1
(en)
|
2021-09-29 |
2023-04-06 |
F. Hoffmann-La Roche Ag |
Rna editing
|
AU2022364838A1
(en)
|
2021-10-15 |
2024-04-11 |
Alnylam Pharmaceuticals, Inc. |
Extra-hepatic delivery irna compositions and methods of use thereof
|
WO2023078883A1
(en)
|
2021-11-03 |
2023-05-11 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating apolipoprotein e4 expression
|
CA3234478A1
(en)
|
2021-11-11 |
2023-05-19 |
Souphalone LUANGSAY |
Pharmaceutical combinations for treatment of hbv
|
WO2023104693A1
(en)
|
2021-12-07 |
2023-06-15 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting actl6b
|
WO2023111210A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
Combination of oligonucleotides for modulating rtel1 and fubp1
|
WO2023111336A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
Oligonucleotide gba agonists
|
WO2023117738A1
(en)
|
2021-12-20 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
WO2023122762A1
(en)
|
2021-12-22 |
2023-06-29 |
Camp4 Therapeutics Corporation |
Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
|
WO2023141507A1
(en)
|
2022-01-20 |
2023-07-27 |
Genentech, Inc. |
Antisense oligonucleotides for modulating tmem106b expression
|
WO2023150553A1
(en)
|
2022-02-01 |
2023-08-10 |
University Of Rochester |
Gpr17 promoter-based targeting and transduction of glial progenitor cells
|
WO2023152369A1
(en)
|
2022-02-14 |
2023-08-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
|
TW202346587A
(zh)
|
2022-02-21 |
2023-12-01 |
瑞士商赫孚孟拉羅股份公司 |
反義寡核苷酸
|
US11931421B2
(en)
|
2022-04-15 |
2024-03-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating myotonic dystrophy
|
WO2023217890A1
(en)
|
2022-05-10 |
2023-11-16 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting cfp-elk1 intergene region
|
WO2023220744A2
(en)
|
2022-05-13 |
2023-11-16 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded loop oligonucleotides
|
WO2023222858A1
(en)
|
2022-05-18 |
2023-11-23 |
F. Hoffmann-La Roche Ag |
Improved oligonucleotides targeting rna binding protein sites
|
WO2023240277A2
(en)
|
2022-06-10 |
2023-12-14 |
Camp4 Therapeutics Corporation |
Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
|
WO2023242324A1
(en)
|
2022-06-17 |
2023-12-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for targeting progranulin
|
WO2024006999A2
(en)
|
2022-06-30 |
2024-01-04 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024040041A1
(en)
|
2022-08-15 |
2024-02-22 |
Dicerna Pharmaceuticals, Inc. |
Regulation of activity of rnai molecules
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
EP4332221A1
(de)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose-nukleinsäure-antisense-oligonukleotide und verfahren dafür
|
WO2024052403A1
(en)
|
2022-09-06 |
2024-03-14 |
F. Hoffmann-La Roche Ag |
Double-stranded rna molecule for administration to the eye
|
WO2024073732A1
(en)
|
2022-09-30 |
2024-04-04 |
Alnylam Pharmaceuticals, Inc. |
Modified double-stranded rna agents
|
CN117510564B
(zh)
*
|
2024-01-08 |
2024-03-08 |
苏州诺维康生物科技有限公司 |
一种医药中间体N2-Ac-5'-O-DMT-2'-O-炔丙基鸟苷的合成方法
|